Please assess the completion status of the following clinical trial:

Trial Title: Mechanisms of Preventing Antibiotic-Associated Diarrhea and the Role for Probiotics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: TRIPLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Has the ability to read, speak, and write in English~2. Has refrigerator (for proper storage of the study yogurt)~3. Has reliable telephone access~4. Is between ages of 18-65 years~5. Agree to refrain from eating yogurts, yogurt drinks, and other foods specified in the provided What Not to Eat list~6. Agree to collect stool samples and participate in follow-up calls as specified~Exclusion Criteria:~1. Diabetes or asthma that requires medication~2. Allergy to strawberry~3. Active diarrhea (three or more loose stools per day for two consecutive days)~4. Any gastrointestinal (or digestive tract) medications, i.e. medicines for irritable bowel syndrome, gastroesophageal (acid) reflux disease, inflammatory bowel disease, etc.~5. History of heart disease, including valvulopathies or cardiac surgery, any implantable device or prosthetic~6. History of gastrointestinal surgery or disease~7. Lactose intolerance that prevents participant from eating yogurt~8. Allergy to milk-protein~9. Allergy to any component of the product or the yogurt vehicle~10. Allergy to penicillin or cephalosporin class antibiotics~11. Allergy to any of the following medications: a) Penicillin; b) Erythromycin; c) Tetracycline; d) Trimethoprim; e) Ciprofloxacin~12. Women who are breastfeeding, pregnant, or planning to become pregnant during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Control (Type: PLACEBO_COMPARATOR): Yogurt without Bifidobacterium animalis subsp. lactis BB-12 (BB-12) and Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet
- BB-12 (Type: EXPERIMENTAL): Bifidobacterium animalis subsp. lactis BB-12 (BB-12)-supplemented yogurt and Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).